Retatrutide: Designed to Last One of the newest GLP-1 medications in development is retatrutide , a triple agonist (GLP-1, GIP, and glucagon receptors) designed with an approximate 6-day half-life , thanks to advanced pharmaceutical engineering
We were particularly concerned about this limitation, as PCSK1 is lowly expressed in adult cells (16)
It is usually not painful but can be bothersome
Kismet typically recommends weekly or monthly treatments based on lab results and symptoms
This overview examines what each peptide is, how they work, their peptide benefits, safety considerations, and guidance on choosing the right approach
[DOI] [PubMed] [Google Scholar] Javitt DC, Grochowski S, Shelley AM, Ritter W